Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses

Journal of the National Cancer Institute

Volumn 104, Issue 19, 2012, Pages 1503-1513

  Kuhn, Elisabetta ^a   Wu, Ren Chin ^a,g   Guan, Bin ^a   Wu, Gang ^b   Zhang, Jinghui ^b   Wang, Yue ^c   Song, Lei ^c   Yuan, Xiguo ^c   Wei, Lei ^b   Roden, Richard B S ^a   Kuo, Kuan Tin ^d   Nakayama, Kentaro ^e   Clarke, Blaise ^f   Shaw, Patricia ^f   Olvera, Narciso ^h   Kurman, Robert J ^h   Levine, Douglas A ^h   Wang, Tian Li ^a   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c State University   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e SHIMANE UNIVERSITY   (Japan)

^f Toronto Health Care System   (Canada)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CARCINOMA;

ADULT; AGED; CARCINOMA IN SITU; CELL CYCLE PROTEINS; CYCLIN E; CYSTADENOCARCINOMA, SEROUS; EXOME; F-BOX PROTEINS; FEMALE; GENE DOSAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PHOSPHATASE 2; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UTERINE NEOPLASMS;

EID: 84867324518     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs345     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17. (Pubitemid 13194678)
3. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642-646. (Pubitemid 43361894)
4. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57-85. (Pubitemid 46448060)
5. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625-632.
6. Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of uterine corpus. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics: Tumors of the Breast and Female Genital Organs, WHO Classification of Tumors. Lyon, France: IARC Press; 2003:217-257.
7. Ellenson LH, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York, NY: Springer; 2011:393-452.
8. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-231.
9. Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226(3):413-420.
10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
11. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH. Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics. 2011;27(6):865-866.
12. Pruitt KD, Tatusova T, Klimke W, Maglott DR. NCBI Reference Sequences: current status, policy and new initiatives. Nucleic Acids Res. 2009;37(Database issue):D32-6.
13. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
14. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329-334.
15. Cancer Genome Research Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
16. Kuo KT, Mao TL, Chen X, et al. DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010;16(7):1997-2008.
17. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69(9):4036-4042.
18. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5(4):557-572. (Pubitemid 41180205)
19. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23(6):657-663. (Pubitemid 46554715)
20. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104(50):20007-20012.
21. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226(3):421-426.
22. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
23. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003;163(4):1255-1260. (Pubitemid 37175075)
24. Samuels Y, Wang Z, Bardelli, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. (Pubitemid 38541907)
25. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-231.
26. Fortier JM, Kornbluth J. NK lytic-associated molecule, involved in NK cytotoxic function, is an E3 ligase. J Immunol. 2006;176(11):6454-6463. (Pubitemid 43787827)
27. Ambrose EC, Kornbluth J. Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells. Apoptosis. 2009;14(10):1227-1236.
28. Kashuba E, Kashuba V, Sandalova T, Klein G, Szekely L. Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase. BMC Cell Biol. 2002;3(8):23.
29. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PloS One. 2006;1(1):e128.
30. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. J Cell Sci. 2003;116(15):3037-3040. (Pubitemid 37038952)
31. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503-533. (Pubitemid 32663902)
32. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003;3(9):695-701. (Pubitemid 37328824)
33. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26(11):1260-1267.
34. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26(11):1268-1274.
35. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150(1):177-185. (Pubitemid 27027108)
36. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20(3):214-219. (Pubitemid 32578105)
37. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814-824. (Pubitemid 30091101)
38. Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol. 1998;29(6):613-619. (Pubitemid 28272717)
39. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113(3):370-373.
40. Shih IeM, Wang TL. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. J Pathol. 2011;224(1):1-4.
41. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8(2):83-93. (Pubitemid 351161321)
42. Onoyama I, Nakayama KI. Fbxw7 in cell cycle exit and stem cell maintenance: insight from gene-targeted mice. Cell Cycle. 2008;7(21):3307-3313.
43. Sancho R, Jandke A, Davis H, Diefenbacher ME, Tomlinson I, Behrens A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology. 2010;139(3):929-941.
44. Onoyama I, Tsunematsu R, Matsumoto A, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med. 2007;204(12):2875-2888. (Pubitemid 350179557)
45. Tan Y, Sangfelt O, Spruck C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett. 2008;271(1):1-12.
46. Akhoondi S, Sun D, Lehr von der N, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67(19):9006-9012. (Pubitemid 47535882)
47. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110-114.
48. Tetzlaff MT, Yu W, Li M, et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA. 2004;101(10):3338-3345. (Pubitemid 38338196)
49. Lee KR, Russell P, Tavassoli FA, et al. Tumors of the ovary and peritoneumsurface epithelial-stromal tumors. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics: Tumors of the Breast and Female Genital Organs, WHO Classification of Tumors. Lyon, France: IARC Press; 2003:113-202.